NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
25021-0206-06 | 25021-0206 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | Intravenous | Nov 28, 2010 | Jun 30, 2017 | No Longer Used |
45963-0614-55 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Mar 12, 2015 | In Use | |
72485-0211-02 | 72485-0211 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2019 | In Use | |
16714-0725-01 | 16714-0725 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jun 15, 2017 | Apr 30, 2020 | In Use |
16714-0726-01 | 16714-0726 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jun 15, 2017 | Apr 30, 2020 | In Use |
45963-0615-56 | 45963-0615 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jan 5, 2015 | In Use | |
58468-0030-02 | 58468-0030 | Thyrotropin Alfa | Thyrogen | 0.9 mg/mL | Hormonal Therapy | Thyroid Stimulating Hormone | Intramuscular | Nov 30, 1998 | In Use | ||
58468-1849-04 | 58468-1849 | Thyrotropin Alfa | Thyrogen | Hormonal Therapy | Thyroid Stimulating Hormone | Nov 30, 1998 | May 30, 2019 | No Longer Used | |||
55513-0078-01 | 55513-0078 | Talimogene Laherparepvec | Imlygic | 1000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
55513-0079-01 | 55513-0079 | Talimogene Laherparepvec | Imlygic | 100000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
55513-0077-01 | 55513-0077 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 10.0 mg/14ml | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | Jun 12, 2024 | In Use | |
80446-0401-01 | 80446-0401 | TEBENTAFUSP | KIMMTRAK | 100.0 ug/.5mL | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | Intravenous | Jan 26, 2022 | In Use | |
57894-0469-01 | 57894-0469 | Talquetamab | TALVEY | 3.0 mg/1.5mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
55513-0059-01 | 55513-0059 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 1.0 mg/1 | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | May 16, 2024 | In Use | |
57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
83205-0001-02 | 83205-0001 | Afamitresgene autoleucel | TECELRA | 10000000000.0 1/1 | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | Intravenous | Aug 2, 2024 | In Use | |
68462-0896-10 | 68462-0896 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 9, 2023 | In Use | ||
00781-3166-95 | 00781-3166 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb 4, 2014 | In Use | ||
00641-6174-01 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Apr 4, 2005 | In Use | ||
64679-0632-01 | 64679-0632 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0634-01 | 64679-0634 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
64679-0635-02 | 64679-0635 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
63323-0377-04 | 63323-0377 | OCTREOTIDE ACETATE | Octreotide | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Mar 14, 2006 | In Use | ||
00078-0184-25 | 00078-0184 | Octreotide Acetate | Sandostatin | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct 21, 1988 | Jan 31, 2019 | In Use | |
15054-1090-04 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sep 1, 2019 | In Use |
Found 11465 results — Export these results